IPL for Dry Eye Disease: What You Can Realistically Expect
Intense Pulsed Light (IPL) therapy has attracted significant interest in eye care over the past decade, and for good reason.
There is a growing body of evidence supporting its use in the management of Meibomian Gland Dysfunction (MGD) — one of the most common drivers of dry eye disease (DED). But like any treatment, IPL works best when patients and clinicians have realistic, evidence-based expectations.
This blog draws on the latest clinical thinking, including the recently published TFOS DEWS III report, to explain what IPL can and cannot do for dry eye treatment, and where it fits in a broader dry eye management plan.
Understanding the Problem: Why MGD Drives Dry Eye
Dry eye disease is not a single condition. TFOS DEWS III — the third iteration of the landmark Tear Film & Ocular Surface Society report — reinforces this point emphatically.
Rather than classifying patients into simple categories of “aqueous deficient” versus “evaporative,” the updated framework recognises that most patients have multiple overlapping drivers of disease. These drivers include:
Tear film instability and abnormal osmolarity
Eyelid and Meibomian gland dysfunction
Ocular surface inflammation and cellular damage
Neurosensory dysfunction
MGD — dysfunction of the oil-secreting glands along the eyelid margin — is among the most prevalent of these drivers.
When the Meibomian glands become blocked or their secretions (meibum) become thickened and inspissated, the lipid layer of the tear film is compromised. This leads to rapid evaporation of tears, surface irritation, and the cascade of symptoms that characterise dry eye: grittiness, burning, intermittent blurred vision, and sensitivity to environmental triggers such as wind or low humidity.
What Is IPL and How Does It Work?
IPL (Intense Pulsed Light) therapy delivers controlled bursts of broad-spectrum light across the periocular skin — specifically from the temple, across the cheekbone, and below the lower eyelid margin. In the context of MGD, it is thought to work through several mechanisms:
Coagulation of abnormal blood vessels (telangiectasia) around the eyelid margin that act as a reservoir for inflammatory mediators
Reduction of inflammatory cytokines that contribute to gland dysfunction and ocular surface damage
Secondary warming of the meibum, which helps to liquefy thickened secretions and improve gland expressibility
Possible reduction in Demodex mite burden, a common contributor to anterior blepharitis and MGD
IPL is typically delivered as a series of sessions — commonly four treatments spaced two to four weeks apart — and is most often combined with Meibomian gland expression (MGX) performed immediately after each session to clear the softened secretions.
What Does the Evidence Actually Say?
Among energy-based therapies for MGD, IPL currently holds the strongest evidence base. Multiple randomised controlled trials have demonstrated meaningful improvements in:
Tear break-up time (TBUT) — a key measure of tear film stability
Meibum quality and gland expressibility
Patient-reported symptoms, including discomfort and visual disturbance
The outcomes are enhanced when IPL is combined with meibomian gland expression, a pattern consistently supported in the literature. Some studies also point to benefits from combining IPL with Low-Level Light Therapy (LLLT/photobiomodulation), though LLLT alone has a smaller evidence base.
It is important to note that while results are statistically and clinically significant at a group level, individual responses vary. Not every patient will experience the same degree of improvement, and some may have a more modest response.
Setting Realistic Expectations: What IPL Is — and Is Not
IPL is an adjunct, not a cure
This is perhaps the single most important point for patients to understand. IPL does not cure dry eye disease or regenerate damaged Meibomian glands.
It is best understood as an adjunctive treatment for moderate to severe or refractory MGD — a way to reduce the inflammatory burden, improve gland function, and create a better environment for the ocular surface to heal.
It should always be used alongside, not instead of, lid hygiene practices and ocular surface optimisation.
It requires a treatment series, not a single session
Patients should be counselled that IPL is not a one-off procedure.
A typical initial course involves three to four sessions, and many patients benefit from periodic maintenance treatments every six to twelve months to sustain results.
Improvements are usually gradual, and the full benefit may not be appreciated until after the second or third session.
Patient selection matters enormously
IPL is most appropriate for patients with documented MGD, rosacea, or telangiectasia-associated lid disease.
It is contraindicated in patients with very dark skin phototypes (Fitzpatrick types V–VI), active ocular infections, or certain photosensitising medications.
Patients with predominantly aqueous-deficient dry eye, neurosensory dry eye, or those whose symptoms are not primarily driven by lid disease are unlikely to benefit significantly.
The underlying dry eye drivers must all be addressed
TFOS DEWS III’s core message is that most dry eye patients have multiple overlapping drivers. Treating only one of them — even effectively — will produce suboptimal results if others are ignored.
A patient who undergoes IPL but neglects Demodex-related anterior blepharitis, continues using preserved topical drops, or has unmanaged ocular surface inflammation is unlikely to achieve the best possible outcomes.
IPL should form one pillar of a comprehensive, driver-based management plan.
How IPL Fits into the DEWS III Framework
One of the key shifts in TFOS DEWS III is the move away from severity-based staging (mild/moderate/severe) toward a driver-based approach. Rather than asking “how bad is the dry eye?”, the framework asks “what is driving this patient’s dry eye, and how do we target it?”
Under the eyelid and MGD treatment algorithm, IPL sits in the escalation tier — appropriate when core therapies (heat, lid hygiene, and blink training) have not provided sufficient relief. It is listed alongside other thermal and mechanical devices, and is explicitly recognised as an evidence-based option for device-assisted MGD management.
Importantly, DEWS III emphasises that the three treatment streams — tear film, eyelids/MGD, and ocular surface inflammation — should be treated in parallel, not sequentially. This means that while IPL is addressing the lid/MGD driver, the clinician should simultaneously consider whether tear film supplementation, anti-inflammatory therapy, or other interventions are also warranted.
Monitoring Response: How Do We Know If It’s Working?
A good clinical workflow should include objective monitoring to guide ongoing management. Useful metrics include:
Symptom questionnaires (e.g., OSDI-6 — with a diagnostic cut-off score of ≥4)
Non-invasive tear break-up time (NIBUT)
Ocular surface staining scores
Meibomian gland expressibility and meibum quality
Meibography (imaging of gland structure, particularly valuable before commencing device-based therapy)
Review at four to six weeks following each treatment cycle is reasonable, though some parameters — particularly meibum quality and patient symptoms — may continue to improve for several weeks after the last session.
What About LLLT and Radiofrequency?
Two other energy-based therapies deserve mention alongside IPL: Low-Level Light Therapy (LLLT) and radiofrequency (RF).
LLLT (Photobiomodulation)
LLLT uses red and near-infrared LED light to stimulate cellular energy production via mitochondrial pathways, reducing oxidative stress and inflammation. Systematic reviews support its use in refractory MGD, though the evidence base remains smaller than for IPL. Combination LLLT and IPL appears to be superior to LLLT alone, suggesting complementary mechanisms.
Radiofrequency (RF)
RF converts electrical energy into controlled heat within the lid tissues, liquefying inspissated meibum and improving gland expressibility. Emerging prospective and sham-controlled trials show improvements in symptoms and gland function, particularly when followed immediately by gland expression. RF is a useful option for patients who may not be suitable for light-based therapies.
Key Takeaways for Patients and Clinicians
IPL has the strongest evidence base among energy-based therapies for MGD-related dry eye disease.
It is an adjunctive treatment — not a standalone cure. It works best alongside lid hygiene, and ocular surface optimisation.
Patient selection is critical: ideal candidates have documented MGD, telangiectasia, or rosacea, and have not responded adequately to conventional therapies.
Realistic expectations include gradual improvement over a series of treatments, with ongoing maintenance sessions likely to be needed.
Under TFOS DEWS III, IPL sits within the eyelid/MGD management algorithm as an escalation therapy, to be used in parallel with treatments targeting other dry eye drivers.
Monitoring with objective metrics is essential to guide ongoing care and confirm response.
Combination approaches — IPL with meibomian gland expression, and potentially LLLT — tend to yield the best outcomes.
Dry eye is a multifactorial, chronic condition that rarely responds to a single intervention. IPL represents a meaningful advance in our ability to address the underlying lid and gland pathology driving so many of our patients’ symptoms. Used appropriately — with clear patient communication, correct selection, and integration into a comprehensive management plan — it can make a genuine difference to quality of life. Used in isolation or with inflated expectations, the results will disappoint.
The goal, as TFOS DEWS III so clearly articulates, is to identify the dominant contributors to each patient’s dry eye and target them explicitly — with education, lifestyle modification, and the right combination of therapies for that individual.
